
Alloplex Biotherapeutics
Founded Year
2016Stage
Series A | AliveTotal Raised
$22.23MLast Raised
$20.67M | 8 mos agoAbout Alloplex Biotherapeutics
Alloplex Biotherapeutics is exploring the order combinatorial space of immunomodulators to develop an anti-tumor vaccine. It offers preclinical research, organoid data analysis, research summaries, and more. The company was founded in 2016 and is based in Woburn, Massachusetts.
Alloplex Biotherapeutics Patents
Alloplex Biotherapeutics has filed 5 patents.
The 3 most popular patent topics include:
- Clusters of differentiation
- Immune system
- Immunology

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
6/11/2020 | 11/30/2021 | Clusters of differentiation, Immune system, Immunology, Human cells, Transcription factors | Grant |
Application Date | 6/11/2020 |
---|---|
Grant Date | 11/30/2021 |
Title | |
Related Topics | Clusters of differentiation, Immune system, Immunology, Human cells, Transcription factors |
Status | Grant |
Latest Alloplex Biotherapeutics News
Feb 27, 2023
Cellular Immunotherapy for Hematological Malignancy and Solid Tumor is under clinical development by Alloplex Biotherapeutics and currently in Phase I for Squamous Cell Carcinoma. According to GlobalData, Phase I drugs for Squamous Cell Carcinoma have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cellular Immunotherapy for Hematological Malignancy and Solid Tumor’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Cellular Immunotherapy for Hematological Malignancy and Solid Tumor overview Cellular therapy is under development for the treatment of hematological malignancies including multiple myeloma, lymphoma, and chronic lymphocytic leukemia and solid tumors including squamous cell carcinoma, ovarian cancer, bladder cancer, transitional cell cancer (urothelial cell cancer), pancreatic cancer. It is administered through intravenous route. It comprises of ex vivo activated autologous peripheral blood mononuclear cells (PBMC). Alloplex Biotherapeutics overview Alloplex Biotherapeutics., is a biotechnology company developing an off-the-shelf anti-tumor vaccine. The company is headquartered in United States. For a complete picture of Cellular Immunotherapy for Hematological Malignancy and Solid Tumor’s drug-specific PTSR and LoA scores, buy the report here. Subscribe to our Newsletter
Alloplex Biotherapeutics Frequently Asked Questions (FAQ)
When was Alloplex Biotherapeutics founded?
Alloplex Biotherapeutics was founded in 2016.
Where is Alloplex Biotherapeutics's headquarters?
Alloplex Biotherapeutics's headquarters is located at 300 Trade Center, Woburn.
What is Alloplex Biotherapeutics's latest funding round?
Alloplex Biotherapeutics's latest funding round is Series A.
How much did Alloplex Biotherapeutics raise?
Alloplex Biotherapeutics raised a total of $22.23M.
Who are the investors of Alloplex Biotherapeutics?
Investors of Alloplex Biotherapeutics include HanAll Biopharma, Daewoong Pharmaceutical and U.S. Small Business Administration.